Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.2DNA damage by radiation
What ifWhat if focused radiation supplied the second antitumor mechanism?
Claim language“one or more mitogen-activated protein kinase (MAPK) pathway inhibitors”
Computed tomography defines the target and nearby organs, and a treatment plan shapes external photon beams around the target. Ionizing radiation generates DNA strand breaks that reduce the ability of irradiated tumor cells to proliferate.
1.2DNA crosslinking with platinum
What ifWhat if a platinum coordination compound supplied the second antitumor mechanism?
Claim language“one or more mitogen-activated protein kinase (MAPK) pathway inhibitors”
A platinum compound forms covalent adducts between neighboring bases in tumor-cell DNA. The adducts stall replication forks and trigger a DNA damage response.
1.2Immune checkpoint blockade
What ifWhat if an immune checkpoint antibody supplied the second antitumor mechanism?
Claim language“one or more mitogen-activated protein kinase (MAPK) pathway inhibitors”
An antibody binds the programmed cell death receptor on activated T cells and blocks engagement by its ligands. This sustains T-cell activity against tumor cells that present recognizable antigens.
1.3Signaling driven by receptor ligands
What ifWhat if the cancer had MAPK pathway activation driven by persistent ligand binding to unmutated receptors?
Claim language“mutations that result in activation of the MAPK pathway”
A secreted growth factor binds a cell-surface receptor tyrosine kinase and sustains signaling through the MAPK cascade. A downstream kinase inhibitor interrupts that signal, and staining for phosphorylated extracellular signal-regulated kinase measures pathway activity in tumor tissue.
1.3Selection by receptor abundance
What ifWhat if a tumor were selected by surface receptor abundance and treated through receptor-directed drug delivery?
Claim language“mutations that result in activation of the MAPK pathway”
Immunohistochemistry measures membrane staining for a cell-surface receptor in a tumor biopsy. An antibody conjugate binds that receptor, enters the cell, and releases a cytotoxic payload after intracellular processing.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Paired treatment in veterinary oncology
A veterinary oncology service uses the oral histone deacetylase inhibitor prodrug and a MAPK pathway inhibitor as separate preparations for a dog with a tumor carrying an activating MAPK pathway mutation. A tumor sequencing report supplies the mutation record, and serial imaging supplies measurements of the same indexed lesions. The veterinary treatment record links administration dates, lesion measurements, and tolerability observations by visit.
Component substitution
Romidepsin replaces the oral prodrug
Romidepsin, an intravenously administered cyclic depsipeptide, supplies the histone deacetylase inhibitor component. The infusion system delivers romidepsin, and a separate oral preparation supplies MAPK pathway inhibition. The treatment record tracks infusion events and oral administrations separately against serial assessments of the mutation-positive tumor.
Parameter or scale variation
Staggered exposure in tumor spheroids
Patient-derived tumor spheroids carrying an activating MAPK pathway mutation occupy a 96-well plate. Three treatment groups receive both inhibitors at hour 0, receive the histone deacetylase inhibitor at hour 0 and the MAPK pathway inhibitor at hour 24, or receive the agents in the reverse order with the same interval. Vehicle and single-agent wells serve as controls, and imaging at hour 72 records spheroid area for each group.
Combination with existing systems
Combination testing in perfused tumor chips
A perfused microfluidic culture system holds mutation-positive tumor organoids in a hydrogel next to a flow channel. Separate reservoirs supply medium containing the histone deacetylase inhibitor prodrug or the MAPK pathway inhibitor, and a mixing junction combines the streams upstream of the culture chamber. An outlet supplies medium for drug concentration measurements, and microscopy records organoid growth during exposure.
Treatment monitoring with plasma sequencing
A sequencing assay measures the activating MAPK pathway variant in cell-free DNA from plasma collected before and during paired inhibitor administration. The assay tags input molecules with unique molecular identifiers and groups reads by identifier to generate consensus sequences. A longitudinal record aligns variant molecules per milliliter of plasma with administration dates and imaging findings.
Automated or data-driven variant
Automated imaging of combination response
A liquid handler dispenses the two inhibitors across a concentration matrix in a multiwell plate containing mutation-positive tumor cells. An automated microscope captures images at baseline and at fixed intervals after dispensing. Image analysis counts nuclei in each well and reports cell count changes relative to the baseline and vehicle controls.
Specific version of a part
Oral precursor in capsules
An oral capsule contains the disulfide precursor of a thiol-bearing cyclic peptide. Reduction in vivo exposes a thiol that coordinates catalytic zinc in histone deacetylases.
Allosteric MEK inhibition
An oral small molecule binds an allosteric pocket in MAPK kinases 1 and 2. Binding reduces phosphorylation of extracellular signal-regulated kinases and lowers downstream pathway activity.
Direct ERK inhibition
A small molecule occupies the ATP-binding pocket of extracellular signal-regulated kinases 1 and 2. Occupancy reduces phosphorylation of downstream substrates such as ribosomal protein S6 kinase.
Activating kinase substitution
Targeted sequencing of tumor DNA detects a valine-to-glutamate substitution at residue 600 of B-type RAF kinase. The substituted kinase drives phosphorylation of MAPK kinase and sustains signaling to extracellular signal-regulated kinase.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.2one or more mitogen-activated protein kinase (MAPK) pathway inhibitors,
As used herein, an “ERK1/2 inhibitor” means those substances that (i) directly interact with ERK1 and/or ERK2, e.g., by binding to ERK1/2 and (ii) decrease the expression or the activity of ERK1 and/or ERK2 protein kinases. Therefore, inhibitors that act upstream of ERK1/2, such as MEK inhibitors and RAF inhibitors, are not ERK1/2 inhibitors according to the present invention (but they are non-ERK MAPK inhibitors).
A · US 2019/0201387 A1 · ¶ 76
Drug inhibitors that target components of the mitogen-activated protein kinases (MAPK) signaling pathway show clinical efficacy in a variety of cancers, particularly those bearing mutations in the BRAF protein kinase.
B · US 10,881,646 B2 · ¶ 4
1.3wherein the cancer harbors one or more mutations that result in activation of the MAPK pathway.
Thus, targeting the MAPK pathway terminal master kinases (ERK1/2) is a promising strategy for tumors harboring such pathway activating alterations (e.g., BRAF, NRAS, and KRAS).
A · US 2019/0201387 A1 · ¶ 281
Thus, targeting the MAPK pathway terminal master kinases (ERK1/2) is a promising strategy for tumors harboring such pathway activating alterations (e.g., BRAF, NRAS, and KRAS).
B · US 10,881,646 B2 · ¶ 302
An empty cell means only that no passage was reproduced there.
Statements in these documents
In view of the foregoing, there is a need for novel targeted agents that would ideally inhibit diverse nodes of oncogenic pathways, and also be effective in combinations by inducing a burden of selective pressures that exceeds the adaptive capacity of diverse cancer genomes.
A · US 2019/0201387 A1 · ¶ 6
One embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy.
A · US 2019/0201387 A1 · ¶ 7
In view of the foregoing, there is a need for novel targeted agents that would ideally inhibit diverse nodes of oncogenic pathways, and also be effective in combinations by inducing a burden of selective pressures that exceeds the adaptive capacity of diverse cancer genomes.
B · US 10,881,646 B2 · ¶ 6
One embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy.
B · US 10,881,646 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355274 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355274/, SHA-256 94d0c2745a9e9d0a5cdf0df9a86a33e06c591dd6926e6d5fa2621e8bcf924a54